Learn languages naturally with fresh, real content!
Popular Topics
Explore By Region
48-week phase 2 study of Sanofi's CD40L antibody frexalimab shows high-efficacy for MS with low relapse rates, leading to global phase 3 studies.
17 months ago
4 Articles